Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 7/20 | 0.44 |
| ▸ | ARG1 | P05089 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.33 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.33 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.33 |
| ▸ | OGA | O60502 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15221802 | 1.00 | DPP4 (0.44) | DPP4ARG1CYP1A2CYP2D6ALOX15 | |
| SCHEMBL14628659 | 1.00 | DPP4 (0.44) | DPP4ARG1CYP1A2CYP2D6ALOX15 | |
| SCHEMBL8294074 | 0.82 | ARG1 (0.40) | DPP4ARG1CYP1A2CYP2D6ALOX15 | |
| SCHEMBL12609037 | 0.82 | ARG1 (0.47) | DPP4ARG1CYP1A2CYP2D6ALOX15 | |
| SCHEMBL3676541 | 0.81 | ARG1 (0.59) | DPP4ARG1CYP1A2CYP2D6ALOX15 | |
| SCHEMBL1512874 | 0.81 | ARG1 (0.59) | DPP4ARG1CYP1A2CYP2D6ALOX15 | |
| SCHEMBL3675363 | 0.81 | ARG1 (0.59) | DPP4ARG1CYP1A2CYP2D6ALOX15 | |
| SCHEMBL4302105 | 0.81 | ARG1 (0.59) | DPP4ARG1CYP1A2CYP2D6ALOX15 | |
| SCHEMBL1512877 | 0.81 | ARG1 (0.59) | DPP4ARG1CYP1A2CYP2D6ALOX15 | |
| SCHEMBL3675362 | 0.81 | ARG1 (0.59) | DPP4ARG1CYP1A2CYP2D6ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037415-B2 | Peptide and pharmaceutical composition for treating an eye disease comprising the same as an active pharmaceutical ingredient | YUYU PHARMA, INC. (KR) | 2024-07-16 | — | — | US | disclosed |
| US-20070004646-A1 | Heterocyclecarbonyl amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004646-A1 | Heterocyclecarbonyl amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | DNPEP, PREP, ANPEP | DPP4 105/4885ARG1 2965/4885CYP1A2 3760/4885 |
| US-12037415-B2 | Peptide and pharmaceutical composition for treating an eye disease comprising the same as an active pharmaceutical ingredient | VIP, IAPP, NGLY1 | DPP4 433/4885ARG1 241/4885CYP1A2 4815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.